Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection

J Clin Immunol. 2022 Jan;42(1):25-27. doi: 10.1007/s10875-021-01119-y. Epub 2021 Aug 23.

Mathieu Paul Rodero^#¹, Stéphane Pelleau^#², Anne Welfringer-Morin³; FJDM study group; Darragh Duffy⁴, Isabelle Melki^{5

6

7}, Brigitte Bader-Meunier^{8

9}; FJDM Study group

¹ Chimie & Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Université Paris Descartes, CNRS, UMR8601, Paris, France.
² Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France.
³ Department of Dermatology, Université de Paris AP-HP-5, Necker-Enfants Malades Hospital, Paris, France.
⁴ Translational Immunology Lab, Institut, Pasteur, Paris, France.
⁵ Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris University, Paris, France.
⁶ General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Robert Debré, Hospital, AP-HP, |Paris, France.
⁷ Department of Paediatric Hematology-Immunology and Rheumatology, Necker-Enfants Malades Hospital, AP-HP, Paris, France, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France.
⁸ Department of Paediatric Hematology-Immunology and Rheumatology, Necker-Enfants Malades Hospital, AP-HP, Paris, France, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France. [email protected].
⁹ Laboratory of Immunogenetics of Paediatric Autoimmunity, Imagine Institute, Inserm U 1163, Paris University, Paris, France. [email protected].

^# Contributed equally.

No abstract available

Publication types